Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: A randomized, placebo-controlled study

American Heart Journal

Volumn 140, Issue 2, 2000, Pages 249-252

  Schrott, Helmut G ^a,b,c   Knapp, Howard ^a,b,c   Davila, Michele ^a,b,c   Shurzinske, Linda ^a,b,c   Black, Donald ^a,b,c  

^a CIGNA Health Care of Oklahoma   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIVER TOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

EID: 0033879569     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.108245     Document Type: Article

References (18)

1. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial
2. Beneficial effects of colestipol-niacin on coronary atherosclerosis: A 4-year follow-up
3. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
4. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
6. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of a centrifuge
7. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Clinics' methodology
8. Enzymatic determination of cholesterol in high-density lipoprotein fractions prepared by a precipitation technique
9. Tables of the numbers of patients required in clinical trials using the log rank test
10. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
11. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
12. Inflammation, aspirin and risks of cardiovascular disease in apparently healthy men
13. Prospective study of C-reactive protein and the risks of future cardiovascular events among apparently healthy women
14. For the Cholesterol and Recurrent Events (CARE) investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein
15. Summary of the second report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol adults (Adult Treatment Panel II)
16. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease: The Heart and Estrogen/Progestin Replacement Study (HERS)
17. Role of a central laboratory in implementing National Cholesterol Education Panel guidelines in rural practices: Model system for managed care